The globalization of pharmaceutical regulation

Governance

Volumn 11, Issue 1, 1998, Pages 1-22

  Vogel, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032337814     PISSN: 09521895     EISSN: None     Source Type: Journal    
DOI: 10.1111/0952-1895.551998055     Document Type: Article

References (65)

1. A Faster Track for New Drugs. 1991. Financial Times December 9:20.
2. Berger, Suzanne. 1996. Introduction. In National Diversity and Global Capitalism, eds., Suzanne Berger and Ronald Dore. Ithaca, NY: Cornell University Press.
3. Bermann, George. 1996. Regulatory Cooperation Between the European Commission and US Administrative Agencies. Administrative Law Journal 9:933-983.
4. Better Medicine to be Side-Effect of New Network. 1996. Nikkei Weekly May 6.
5. Braithwaite, John. 1994. Prospects for Win-Win International Rapproachement of Regulation. In Regulatory Co-operation for an Interdependent World. Paris: OECD.
6. Buono, Teresa. 1995. Biotechnology-Derived Pharmaceuticals: Harmonizing Regional Regulation. Suffolk Transnational Law Review 18:133.
7. Cecchini, Paolo. 1988. The European Challenge, 1992. Aldershot, England: Wildwood House.
8. Contrera, Joseph. 1995. Comment: The Food and Drug Administration and the International Conference on Harmonization: How Harmonious Will International Pharmaceutical Regulations Become? Administrative Law Journal 9:928-960.
9. Cookson, Clive. 1990. Prescription for Success: The Japanese Prefer their Own Medicines. Financial Times December 3.
10. Currie, William. 1989. Drug Development and Registration in Japan: Threshold of Transition. Bioscience 33:100-8.
11. Dillman, John. 1991. Prescription of Drug Approval and Terminal Diseases: Desperate Times Require Desperate Measures. Vanderbilt Law Review 44:926-950.
12. Drug Regulation. 1991. Economist November 16:84.
13. EC, USA and Japan Ready to Reduce Pharmaceutical Product-testing and Animal Tests Drastically. 1991. Rapid. Commission of the European Communities. November 13.
14. ECC (European Community Commission). 1963 (September 16). Press release IP 63:156.
15. EEC/US/Japan: Major Agreement on Pharmaceutical Trials. 1991. European Environment November 26.
16. EMEA Doors Now Open for Business. 1995. Marketletter February 6.
17. EMEA Status Report. 1996. October 21.
18. Euro Commission, EMEAConsider Global Dossier. 1996. IAC Industry Express June 6.
19. FDA Challenged by its Involvement in International Harmonization Efforts. 1996. BNA Health Care Daily. January 19.
20. Funding for Japan's "Pharma Dream 21." 1992. Marketletter January 20.
21. Global harmonization on Pharmaceutical Regulations a Step Nearer. 1991. Pharmaceutical Business News; Financial Times November 15.
22. Green, Daniel. 1997. Fast-track to Approval. Financial Times April 24.
23. _. 1995a. EU Body to Speed Up Approval of New Drugs. Financial Times January 26.
24. _. 1995b. European Medicines Evaluation Agency: Fast-track Appovals Service. Financial Times April 25.
25. Hancher, Leigh. 1990. Regulating for Competition: Government, Law, and the Pharmaceutical Industry in the United Kingdom and France. Oxford: Clarendon Press.
26. Hirschler, Ben. 1994. Reuter European Community Report July 4.
27. Horton, Linda R. 1997. The Food and Drug Administration's International Harmonization, Enforcement, and Trade Policy Activities. Fundamentals of Law & Regulation. FDLI:99-159.
28. Howells, J. 1992. Pharmaceuticals and Europe 1992: The Dynamics of Industrial Change. Environment and Planning 29:33-49.
29. Hudgins, Edward L. 1997. Future of the FDA. Regulation Winter 18:56.
30. ICH - A Great Success. 1995. Daily News Biotechnology and Medical Technology December 11.
31. Impact of First ICH Guidelines. 1995. Information Access Company Newsletter Database October 30.
32. Internal Market Council: Belgium Opposes Medicine Evaluation Agency. 1994. European Report. December 10.
33. Japan Urgently Needs Better Quality Clinical Trials. 1995. Pharma Japan March 20.
34. Japan: Mr. Fujii of PAB Indicates Koseisho's Strong Commitment to GCP and ICH. 1992. Pharma Japan August 31.
35. Jordan, David. 1992. International Regulatory Harmonization: A New Era in Prescription Drug Approval. Vanderbilt Journal of Transnational Law 25:471-505.
36. Kanusky, Rosemary. 1994. Pharmaceutical Harmonization in the United States, the European Economic Community and Japan. Houston Journal of International Law 16:665-707.
37. Kapstein, Ethan Barnaby. 1992. Between Power and Purpose: Central Bankers and the Politics of Regulatory Convergence. International Organization 46.
38. Katz, Eric M. 1993. Europe's Centralized New Drug Procedures: Is the United States Prepared to Keep Pace? Food and Drug Law Journal 48:577-587.
39. Kaufer, Eric. 1989. The Regulation of Drug Development: In Search of a Common European Approach. EUI Working Paper No. 89/411. Florence: European University Institute.
40. Kidd, Dan. 1997. The International Conference on Pharmaceutical Regulations, the European Medicines Evaluation Agency, and the FDA: Who's Zooming Who? Indiana Journal of Global Legal Studies 4:183-206.
41. Kingham, Richard, Peter Bogaert, and Pamela Eddy. 1994. The New European Medicines Agency. The Food and Drug Law Journal 49:301-321.
42. Koberstein, Wayne. 1996. Fernand Sauer: Tending the Garden. Pharmaceutical Executive 16:36-7.
43. Lindemann, Eric. 1994. Importing AIDS Drugs: Food and Drug Administration Policy and its Limitations. George Washington Journal of International Law and Economics 28:133-169.
44. Marsh, Peter. 1990. A Suitable Case for Treatment. Financial Times August 22:17.
45. Mauer, P. Reed. 1996. View from Tokyo: Big Boss Era Is Ending. Daily News Biotechnology and Medical Technology June 24.
46. Melloan, George. 1994. Why Europeans are being Shorted on Miracle Drugs. Wall Street Journal April 18: A13.
47. Mintz, Morton. 1996. Remembering Thalidomide. Washington Post National Weekly Edition July 22.
48. Oraz, Luis, Kenneth Kaitin and Louis Lasagna. 1992. Pharmaceutical Regulation in the European Community: Barriers to Single Market Integration. Journal of Health Politics, Policy and Law 17:859-861.
49. Perry, Susan. 1994. Drugs Companies Alarmed by EU Medicines Agency Delay. Reuter European Community Report December 28.
50. Pharmaceuticals: Carving Up Europe's Drugs Industry. 1995. Economist August 26:57.
51. Proposals to Reform Drug Regulation Law. 1979. Washington DC: American Enterprise Institute.
52. Regulatory Co-operation for an Interdependent World. 1994. Paris: OECD.
53. Relihan, Julie C. 1995. Expediting FDA Approval of AIDS Drugs: An International Approach. Boston University International Law Journal 13:229-261.
54. Richards, Tessa. 1991. Medicine in Europe: 1992 and All That. British Medical Journal 303:116-119.
55. _. 1994. How Should European Health Policy Be Developed? British Medical Journal 309:116.
56. Sauer, Fernand. 1991. Harmonization of Biotechnological Regulations in the European Community. In Drug Biotechnology Regulation: Scientific Basis and Practices, eds., Yuan-yuan H. Chiu and John L. Gueriguian. New York: M. Dekker.
57. Scheurer, James. 1980. The FDA: Too Slow. New York Times May 22.
58. Swire, Peter. 1996. The Race to Laxity and the Race to Undesirability: Explaining Failures in Competition Among Jurisdictions in Environmental Law. Yale Law and Policy Review/Yale Journal of Regulation (Symposium Issue) 14:66-110.
59. Sykes, Alan. 1995. Product Standards for Internationally Trade Goods Markets. Washington DC: Brookings Institution.
60. Tarabusi, Claudio and Graham Vickery. 1993. Globalization and Pharmaceuticals. OECD Observer 185:41.
61. van de Gevel, A.J.W. 1992. The Pharmaceutical Industry. CEPS Working Paper No. 42.
62. Vogel, David. 1995. Trading Up: Consumer and Environmental Regulation in a Global Economy. Cambridge: Harvard University Press.
63. _. 1990. When Consumers Oppose Consumer Protection: The Politics of Regulatory Backlash. Journal of Public Policy October-December, 10:449-470.
64. Webster's Ninth Collegiate Dictionary. 1978. New York: Mirriam-Webster.
65. Wechsler, Jill. 1996. Washington vs. the World? Pharmaceutical Executive 16:16-20.